| C576882 | 1-(2-trifluoromethoxyphenyl)-2-nitroethanone | 1-(2-trifluoromethoxyphenyl)-2-nitroethanone results in decreased expression of ABL1 protein | 22527513 |
| C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[ABL1 protein results in increased phosphorylation of and results in decreased activity of PPARG protein] which results in increased expression of COL1A1 protein] | 17030193 |
| C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine] | 16849647 |
| C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA] | 16849647 |
| C488288 | 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid | "[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein" | 21214929 |
| C488288 | 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid | "[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein" | 21214929 |
| C488288 | 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid | "[[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in decreased expression of BCL2 protein" | 21214929 |
| C488288 | 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid | "[[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of BAX protein" | 21214929 |
| C488288 | 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid | "[[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of FAS protein" | 21214929 |
| C488288 | 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid | "[[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein" | 21214929 |
| C488288 | 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid | "[[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of TNFRSF10B protein" | 21214929 |
| C488288 | 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid | "[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein" | 21214929 |
| C488288 | 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid | "[[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein" | 21214929 |
| C488288 | 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid | "[[[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in decreased expression of BCL2 protein" | 21214929 |
| C488288 | 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid | "[[[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of BAX protein" | 21214929 |
| C488288 | 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid | "[[[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of FAS protein" | 21214929 |
| C488288 | 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid | "[[[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein" | 21214929 |
| C488288 | 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid | "[[[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of TNFRSF10B protein" | 21214929 |
| C472791 | 3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid | 3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid results in increased expression of ABL1 mRNA | 16788091 |
| C575425 | (4-(4'-chloro-2'-fluoro)phenylamino)-6,7-dimethylquinazoline | "(4-(4'-chloro-2'-fluoro)phenylamino)-6,7-dimethylquinazoline results in decreased activity of ABL1 protein" | 22573732 |
| C498826 | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide | [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide co-treated with arsenic trioxide] results in decreased phosphorylation of ABL1 protein | 23883479 |
| C498826 | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein] | 19878872 |
| C498826 | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABL1 protein results in increased phosphorylation of ABL1 protein] | 19878872 |
| C498826 | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine] | 16849647 |
| C498826 | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA] | 16849647 |
| C498826 | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased phosphorylation of ABL1 protein | 23883479 |
| C498826 | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased phosphorylation of ABL1 protein mutant form | 19878872 |
| C498826 | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased activity of ABL1 protein | 18632630|2190843 |
| C094411 | 4-phenylcoumarin | 4-phenylcoumarin analog results in increased expression of ABL1 mRNA | 27773722 |
| D000079 | Acetaldehyde | ABL1 protein promotes the reaction [Acetaldehyde results in increased phosphorylation of and results in decreased activity of PPARG protein] | 17030193 |
| D000079 | Acetaldehyde | Acetaldehyde results in increased activity of ABL1 protein | 17030193 |
| D000079 | Acetaldehyde | Imatinib Mesylate inhibits the reaction [Acetaldehyde results in increased activity of ABL1 protein] | 17030193 |
| D000082 | Acetaminophen | Acetaminophen results in increased expression of ABL1 mRNA | 29067470 |
| D000082 | Acetaminophen | Acetaminophen affects the expression of ABL1 mRNA | 17562736 |
| D000111 | Acetylcysteine | Acetylcysteine inhibits the reaction [NSC 680410 results in decreased phosphorylation of ABL1 protein] | 16481037 |
| D000255 | Adenosine Triphosphate | [ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein | 19366808 |
| D000255 | Adenosine Triphosphate | sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] | 19366808 |
| D000447 | Aldehydes | Aldehydes results in decreased expression of ABL1 mRNA | 25014914 |
| C077990 | alvocidib | [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein | 15039284 |
| C077990 | alvocidib | [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein | 15039284 |
| C077990 | alvocidib | [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein | 15039284 |
| D000638 | Amiodarone | Amiodarone results in increased expression of ABL1 mRNA | 19774075 |
| D000643 | Ammonium Chloride | Ammonium Chloride results in increased expression of ABL1 protein | 16483693 |
| C058317 | arsenic disulfide | arsenic disulfide results in decreased activity of ABL1 protein | 12421474 |
| C058317 | arsenic disulfide | arsenic disulfide results in decreased expression of and results in decreased activity of ABL1 protein mutant form | 12421474 |
| C006632 | arsenic trioxide | [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide co-treated with arsenic trioxide] results in decreased phosphorylation of ABL1 protein | 23883479 |
| C006632 | arsenic trioxide | ABL1 protein affects the susceptibility to arsenic trioxide | 10648417 |
| C006632 | arsenic trioxide | [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein | 17495969 |
| C006632 | arsenic trioxide | arsenic trioxide results in decreased expression of ABL1 mRNA | 20458559 |
| C006632 | arsenic trioxide | arsenic trioxide results in decreased expression of ABL1 protein | 10648417 |
| C006632 | arsenic trioxide | arsenic trioxide results in decreased expression of ABL1 protein mutant form | 14633726 |
| C006632 | arsenic trioxide | arsenic trioxide results in decreased expression of [BCR protein mutant form binds to ABL1 protein mutant form] | 24129092 |
| C006632 | arsenic trioxide | [Tretinoin co-treated with arsenic trioxide] results in increased expression of ABL1 mRNA | 15894607 |
| D001285 | Atropine | [Parathion co-treated with Atropine] results in increased expression of ABL1 mRNA | 17390078 |
| C487081 | belinostat | belinostat results in decreased expression of ABL1 mRNA | 19606018 |
| D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | "7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of ABL1 mRNA" | 19150397 |
| C044887 | beta-methylcholine | beta-methylcholine affects the expression of ABL1 mRNA | 21179406 |
| C006780 | bisphenol A | bisphenol A results in increased expression of ABL1 mRNA | 23704952 |
| C006780 | bisphenol A | bisphenol A affects the expression of ABL1 mRNA | 25181051 |
| D000069286 | Bortezomib | [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein | 15039284 |
| D000069286 | Bortezomib | [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein | 15039284 |
| D000069286 | Bortezomib | [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein | 15039284 |
| D000069286 | Bortezomib | [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein | 17495969 |
| D000069286 | Bortezomib | "[Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein" | 21195056 |
| D000069286 | Bortezomib | Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein] | 15039284 |
| C471992 | bosutinib | bosutinib results in decreased activity of ABL1 protein | 17114238 |
| C018475 | butyraldehyde | butyraldehyde results in decreased expression of ABL1 mRNA | 26079696 |
| D019256 | Cadmium Chloride | [Methylnitronitrosoguanidine co-treated with Cadmium Chloride] results in increased expression of ABL1 mRNA | 19840844 |
| D002211 | Capsaicin | Capsaicin results in increased expression of ABL1 mRNA | 19502594 |
| D002251 | Carbon Tetrachloride | Carbon Tetrachloride results in increased phosphorylation of ABL1 protein | 17030193 |
| D002251 | Carbon Tetrachloride | Imatinib Mesylate inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of ABL1 protein] | 17030193 |
| D060729 | Coal Ash | Coal Ash results in increased expression of ABL1 mRNA | 19000753 |
| D003042 | Cocaine | Cocaine affects the expression of ABL1 mRNA | 15681117 |
| D003300 | Copper | [Thiosemicarbazones binds to Copper] which results in increased expression of ABL1 protein | 20931265 |
| C408982 | CPG-oligonucleotide | CPG-oligonucleotide results in increased expression of ABL1 mRNA | 21878529 |
| C551994 | crizotinib | crizotinib results in decreased activity of ABL1 protein | 21812414 |
| D003471 | Cuprizone | Cuprizone results in decreased expression of ABL1 mRNA | 27523638 |
| C093628 | cyproconazole | [cyproconazole co-treated with epoxiconazole] results in increased expression of ABL1 mRNA | 29038839 |
| D015638 | Cytochalasin D | Cytochalasin D results in increased phosphorylation of ABL1 protein | 21900236 |
| D015638 | Cytochalasin D | EGF protein inhibits the reaction [Cytochalasin D results in increased phosphorylation of ABL1 protein] | 21900236 |
| D000069439 | Dasatinib | Dasatinib binds to ABL1 protein | 17684099|1818038 |
| D000069439 | Dasatinib | Dasatinib binds to ABL1 protein mutant form | 17684099|1818038 |
| D000069439 | Dasatinib | [Dasatinib co-treated with vorinostat] results in decreased expression of ABL1 protein mutant form | 17020995 |
| D000069439 | Dasatinib | [Dasatinib co-treated with vorinostat] results in decreased phosphorylation of ABL1 protein mutant form | 17020995 |
| D000069439 | Dasatinib | Dasatinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein] | 19100678|1987887 |
| D000069439 | Dasatinib | Dasatinib inhibits the reaction [ABL1 protein results in increased phosphorylation of ABL1 protein] | 19878872 |
| D000069439 | Dasatinib | Dasatinib results in decreased activity of ABL1 protein mutant form | 19100678 |
| D000069439 | Dasatinib | Dasatinib results in decreased phosphorylation of ABL1 protein mutant form | 17020995|1987887 |
| D000069439 | Dasatinib | Dasatinib binds to ABL1 protein | 17684099 |
| D000069439 | Dasatinib | Dasatinib results in decreased activity of ABL1 protein | 17114238|2112860 |
| D003630 | Daunorubicin | ABL1 results in decreased susceptibility to Daunorubicin | 12410571 |
| C560099 | DCC-2036 | DCC-2036 results in decreased activity of ABL1 protein | 21908430 |
| D002945 | Cisplatin | ABL1 protein results in increased susceptibility to Cisplatin | 21324906 |
| D002945 | Cisplatin | "[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein" | 21214929 |
| D002945 | Cisplatin | "[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein" | 21214929 |
| D002945 | Cisplatin | "[[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in decreased expression of BCL2 protein" | 21214929 |
| D002945 | Cisplatin | "[[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of BAX protein" | 21214929 |
| D002945 | Cisplatin | "[[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of FAS protein" | 21214929 |
| D002945 | Cisplatin | "[[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein" | 21214929 |
| D002945 | Cisplatin | "[[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of TNFRSF10B protein" | 21214929 |
| D002945 | Cisplatin | [Cisplatin co-treated with jinfukang] results in decreased expression of ABL1 mRNA | 27392435 |
| D002945 | Cisplatin | [Cisplatin co-treated with panobinostat] affects the expression of ABL1 mRNA | 21791302 |
| D002945 | Cisplatin | Cisplatin results in decreased expression of ABL1 mRNA | 27392435 |
| D002945 | Cisplatin | Cisplatin results in increased expression of ABL1 protein | 22023808 |
| D004004 | Dichlororibofuranosylbenzimidazole | Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein] | 15039284 |
| D004004 | Dichlororibofuranosylbenzimidazole | Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein | 15039284 |
| C000944 | dicrotophos | dicrotophos results in increased expression of ABL1 mRNA | 28302478 |
| D002117 | Calcitriol | Calcitriol results in increased expression of ABL1 mRNA | 21592394 |
| D002117 | Calcitriol | [Testosterone co-treated with Calcitriol] results in increased expression of ABL1 mRNA | 21592394 |
| D019813 | 1,2-Dimethylhydrazine | "1,2-Dimethylhydrazine results in increased expression of ABL1 mRNA" | 27840820 |
| D004317 | Doxorubicin | "[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein" | 21214929 |
| D004317 | Doxorubicin | "[[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein" | 21214929 |
| D004317 | Doxorubicin | "[[[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in decreased expression of BCL2 protein" | 21214929 |
| D004317 | Doxorubicin | "[[[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of BAX protein" | 21214929 |
| D004317 | Doxorubicin | "[[[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of FAS protein" | 21214929 |
| D004317 | Doxorubicin | "[[[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein" | 21214929 |
| D004317 | Doxorubicin | "[[[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of TNFRSF10B protein" | 21214929 |
| C109476 | epoxiconazole | [cyproconazole co-treated with epoxiconazole] results in increased expression of ABL1 mRNA | 29038839 |
| D004967 | Estrogens | ABL1 protein results in increased susceptibility to Estrogens | 20234815 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol affects the expression of ABL1 mRNA | 17555576 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in increased expression of ABL1 mRNA | 17942748 |
| D004997 | Ethinyl Estradiol | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ABL1 mRNA | 17942748 |
| C069837 | fullerene C60 | fullerene C60 results in increased expression of ABL1 mRNA | 19167457 |
| D005707 | Gallic Acid | Gallic Acid promotes the reaction [Imatinib Mesylate results in decreased phosphorylation of [BCR protein mutant form binds to ABL1 protein mutant form]] | 22245431 |
| D005707 | Gallic Acid | Gallic Acid results in decreased phosphorylation of [BCR protein mutant form binds to ABL1 protein mutant form] | 22245431 |
| D005707 | Gallic Acid | Imatinib Mesylate promotes the reaction [Gallic Acid results in decreased phosphorylation of [BCR protein mutant form binds to ABL1 protein mutant form]] | 22245431 |
| D006046 | Gold | [Polyethyleneimine binds to Gold] which results in decreased expression of ABL1 mRNA | 28433809 |
| D006632 | Histamine | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine] | 16849647 |
| D006632 | Histamine | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine] | 16849647 |
| D006632 | Histamine | [BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine | 16849647 |
| D006632 | Histamine | Imatinib Mesylate inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine] | 16849647 |
| D006861 | Hydrogen Peroxide | Hydrogen Peroxide affects the expression of ABL1 protein | 21179406 |
| D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in increased activity of ABL1 protein | 17030193 |
| D006861 | Hydrogen Peroxide | Imatinib Mesylate inhibits the reaction [Hydrogen Peroxide results in increased activity of ABL1 protein] | 17030193 |
| C492448 | ICG 001 | ICG 001 results in increased expression of ABL1 mRNA | 26191083 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate results in decreased phosphorylation of ABL1 protein | 12032135 |
| D000068877 | Imatinib Mesylate | ABL1 mutant form results in increased susceptibility to Imatinib Mesylate | 15107311 |
| D000068877 | Imatinib Mesylate | ABL1 protein results in decreased susceptibility to Imatinib Mesylate | 15039284 |
| D000068877 | Imatinib Mesylate | Gallic Acid promotes the reaction [Imatinib Mesylate results in decreased phosphorylation of [BCR protein mutant form binds to ABL1 protein mutant form]] | 22245431 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein] | 19878872 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate inhibits the reaction [ABL1 protein results in increased phosphorylation of ABL1 protein] | 19878872 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate inhibits the reaction [Acetaldehyde results in increased activity of ABL1 protein] | 17030193 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine] | 16849647 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA] | 16849647 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of ABL1 protein] | 17030193 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate inhibits the reaction [Hydrogen Peroxide results in increased activity of ABL1 protein] | 17030193 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate promotes the reaction [Gallic Acid results in decreased phosphorylation of [BCR protein mutant form binds to ABL1 protein mutant form]] | 22245431 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate results in decreased activity of ABL1 protein mutant form | 15329907 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate results in decreased expression of [BCR protein mutant form binds to ABL1 protein mutant form] | 22397755 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate results in decreased phosphorylation of ABL1 protein mutant form | 19366808|1987887 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate results in decreased phosphorylation of [BCR protein mutant form binds to ABL1 protein mutant form] | 22245431 |
| D000068877 | Imatinib Mesylate | [vorinostat co-treated with Imatinib Mesylate] results in decreased expression of ABL1 protein mutant form | 12446442 |
| D000068877 | Imatinib Mesylate | [vorinostat co-treated with Imatinib Mesylate] results in decreased phosphorylation of ABL1 protein mutant form | 12446442 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate results in decreased expression of ABL1 mutant form | 16481037 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate results in decreased expression of ABL1 protein | 16481037 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate results in decreased phosphorylation of ABL1 protein | 12032135 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate analog results in decreased activity of ABL1 protein modified form | 15501042 |
| D000068877 | Imatinib Mesylate | Imatinib Mesylate results in decreased activity of ABL1 protein | 16940797|2190843 |
| C544151 | jinfukang | [Cisplatin co-treated with jinfukang] results in decreased expression of ABL1 mRNA | 27392435 |
| D008070 | Lipopolysaccharides | Lipopolysaccharides results in increased expression of ABL1 mRNA | 12057914 |
| C013592 | mangiferin | mangiferin results in decreased expression of ABL1 mRNA | 15498116 |
| D008628 | Mercury | Mercury results in increased expression of ABL1 mRNA | 19937285 |
| D008694 | Methamphetamine | Methamphetamine results in increased expression of ABL1 mRNA | 26307267 |
| C004925 | methylmercuric chloride | methylmercuric chloride results in increased expression of ABL1 mRNA | 20061341 |
| D008769 | Methylnitronitrosoguanidine | [Methylnitronitrosoguanidine co-treated with Cadmium Chloride] results in increased expression of ABL1 mRNA | 19840844 |
| D008769 | Methylnitronitrosoguanidine | [Methylnitronitrosoguanidine co-treated with Okadaic Acid] results in increased expression of ABL1 mRNA | 19840844 |
| D008769 | Methylnitronitrosoguanidine | [Methylnitronitrosoguanidine co-treated with Tetradecanoylphorbol Acetate] results in increased expression of ABL1 mRNA | 19840844 |
| C005246 | myristicin | myristicin results in decreased expression of ABL1 mRNA | 24792648 |
| C455139 | myrtucommulone A | myrtucommulone A results in decreased expression of ABL1 mRNA | 26032814 |
| C017558 | nickel sulfide | [[[nickel sulfide results in increased methylation of MIR203A promoter] co-treated with [nickel sulfide results in increased methylation of MIR203A exon]] results in decreased expression of MIR203A mRNA] which affects the expression of ABL1 | 23968727 |
| D015112 | 4-Nitroquinoline-1-oxide | 4-Nitroquinoline-1-oxide results in decreased expression of ABL1 mRNA | 22561872 |
| D015112 | 4-Nitroquinoline-1-oxide | 4-Nitroquinoline-1-oxide results in increased expression of ABL1 mRNA | 22561872 |
| C061800 | N,N-dimethylsphingosine | "[Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein" | 21195056 |
| C044387 | N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine | "N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in decreased expression of ABL1 mRNA" | 12756304 |
| C404397 | NSC 680410 | Acetylcysteine inhibits the reaction [NSC 680410 results in decreased phosphorylation of ABL1 protein] | 16481037 |
| C404397 | NSC 680410 | NSC 680410 affects the phosphorylation of and affects the expression of ABL1 mutant form | 16481037 |
| C404397 | NSC 680410 | NSC 680410 results in decreased phosphorylation of and affects the expression of ABL1 protein | 16481037 |
| D019319 | Okadaic Acid | [Methylnitronitrosoguanidine co-treated with Okadaic Acid] results in increased expression of ABL1 mRNA | 19840844 |
| C496932 | panobinostat | [Cisplatin co-treated with panobinostat] affects the expression of ABL1 mRNA | 21791302 |
| D010269 | Paraquat | Paraquat results in increased expression of ABL1 mRNA | 18836921 |
| D010278 | Parathion | [Parathion co-treated with Atropine] results in increased expression of ABL1 mRNA | 17390078 |
| D010278 | Parathion | Parathion results in increased expression of ABL1 mRNA | 17390078 |
| C410127 | PCB 180 | PCB 180 affects the expression of ABL1 mRNA | 21703328 |
| C011272 | perfosfamide | perfosfamide results in increased expression of ABL1 mRNA | 19429390 |
| D010634 | Phenobarbital | Phenobarbital results in decreased methylation of ABL1 gene | 19233941 |
| D010634 | Phenobarbital | Phenobarbital results in decreased methylation of ABL1 promoter | 19482888 |
| D010634 | Phenobarbital | Phenobarbital results in increased expression of ABL1 mRNA | 19482888 |
| D010656 | Phenylephrine | ABL1 protein affects the reaction [Phenylephrine promotes the reaction [BCAR1 protein binds to CRK protein]] | 17615370 |
| D010656 | Phenylephrine | ABL1 protein affects the reaction [Phenylephrine promotes the reaction [CRK protein binds to WASL protein]] | 17615370 |
| D010656 | Phenylephrine | ABL1 protein affects the reaction [Phenylephrine results in increased phosphorylation of BCAR1 protein] | 17615370 |
| D010656 | Phenylephrine | ABL1 protein affects the susceptibility to Phenylephrine | 17615370 |
| D010656 | Phenylephrine | Phenylephrine results in increased phosphorylation of ABL1 protein | 17615370 |
| D011094 | Polyethyleneimine | [Polyethyleneimine binds to Gold] which results in decreased expression of ABL1 mRNA | 28433809 |
| C545373 | ponatinib | ponatinib analog results in decreased activity of ABL1 protein | 21561767 |
| C545373 | ponatinib | ponatinib analog results in decreased activity of ABL1 protein mutant form | 21561767 |
| C545373 | ponatinib | ponatinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of ABL1 protein mutant form] | 19878872 |
| C545373 | ponatinib | ponatinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein] | 19878872 |
| C545373 | ponatinib | ponatinib inhibits the reaction [ABL1 protein results in increased phosphorylation of ABL1 protein] | 19878872 |
| C545373 | ponatinib | ponatinib results in decreased activity of ABL1 protein | 19878872|2156176 |
| C545373 | ponatinib | ponatinib results in decreased activity of ABL1 protein mutant form | 19878872|2051315 |
| C545373 | ponatinib | ponatinib results in decreased phosphorylation of ABL1 protein | 25304212 |
| C545373 | ponatinib | ponatinib results in decreased phosphorylation of ABL1 protein mutant form | 19878872 |
| C545373 | ponatinib | ponatinib binds to and results in decreased activity of ABL1 protein mutant form | 21118377 |
| C545373 | ponatinib | ponatinib results in decreased activity of ABL1 protein | 21482694|2190843 |
| D011189 | Potassium Chloride | ABL1 protein affects the reaction [Potassium Chloride results in increased phosphorylation of BCAR1 protein] | 17615370 |
| D011189 | Potassium Chloride | ABL1 protein affects the susceptibility to Potassium Chloride | 17615370 |
| D011189 | Potassium Chloride | Potassium Chloride results in increased phosphorylation of ABL1 protein | 17615370 |
| C470893 | purmorphamine | purmorphamine inhibits the reaction [resveratrol results in decreased expression of [BCR protein mutant form binds to ABL1 protein mutant form]] | 22397755 |
| D011794 | Quercetin | Quercetin results in decreased expression of ABL1 protein | 19207037 |
| C059514 | resveratrol | purmorphamine inhibits the reaction [resveratrol results in decreased expression of [BCR protein mutant form binds to ABL1 protein mutant form]] | 22397755 |
| C059514 | resveratrol | resveratrol results in decreased expression of [BCR protein mutant form binds to ABL1 protein mutant form] | 22397755 |
| C085746 | rottlerin | rottlerin inhibits the reaction [[ABL1 protein results in increased phosphorylation of and results in decreased activity of PPARG protein] which results in increased expression of COL1A1 protein] | 17030193 |
| C513635 | S-2-pentyl-4-pentynoic hydroxamic acid | S-2-pentyl-4-pentynoic hydroxamic acid results in increased expression of ABL1 mRNA | 21427059 |
| C524947 | Scutellaria barbata extract | Scutellaria barbata extract results in decreased expression of ABL1 protein | 16218664 |
| C017947 | sodium arsenite | sodium arsenite results in increased expression of ABL1 mRNA | 12016162 |
| C017947 | sodium arsenite | sodium arsenite results in decreased expression of ABL1 mRNA | 16014739 |
| C471405 | sorafenib | sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] | 19366808 |
| C471405 | sorafenib | sorafenib results in decreased activity of ABL1 protein mutant form | 19366808 |
| C471405 | sorafenib | sorafenib results in decreased phosphorylation of ABL1 protein mutant form | 19366808 |
| D013629 | Tamoxifen | ABL1 protein results in decreased susceptibility to Tamoxifen | 20234815 |
| D013629 | Tamoxifen | Tamoxifen affects the expression of ABL1 mRNA | 17555576 |
| D013739 | Testosterone | [Testosterone co-treated with Calcitriol] results in increased expression of ABL1 mRNA | 21592394 |
| D013739 | Testosterone | Testosterone results in increased expression of ABL1 mRNA | 21592394 |
| C020806 | tetrabromobisphenol A | tetrabromobisphenol A results in decreased expression of ABL1 mRNA | 28970181 |
| D013749 | Tetrachlorodibenzodioxin | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ABL1 mRNA | 17942748 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of ABL1 mRNA | 26290441 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased expression of ABL1 mRNA | 17942748 |
| D013755 | Tetradecanoylphorbol Acetate | [Methylnitronitrosoguanidine co-treated with Tetradecanoylphorbol Acetate] results in increased expression of ABL1 mRNA | 19840844 |
| D013882 | Thiosemicarbazones | [Thiosemicarbazones binds to Copper] which results in increased expression of ABL1 protein | 20931265 |
| D014212 | Tretinoin | [Tretinoin co-treated with arsenic trioxide] results in increased expression of ABL1 mRNA | 15894607 |
| D014212 | Tretinoin | Tretinoin results in increased expression of ABL1 mRNA | 16788091 |
| C012589 | trichostatin A | trichostatin A results in decreased expression of ABL1 mRNA | 19606018|2377000 |
| D014635 | Valproic Acid | Valproic Acid affects the expression of ABL1 mRNA | 25979313 |
| D014635 | Valproic Acid | Valproic Acid results in increased expression of ABL1 mRNA | 21427059 |
| D014639 | Vanadium | Vanadium results in increased expression of ABL1 mRNA | 19000753 |
| C111237 | vorinostat | [Dasatinib co-treated with vorinostat] results in decreased expression of ABL1 protein mutant form | 17020995 |
| C111237 | vorinostat | [Dasatinib co-treated with vorinostat] results in decreased phosphorylation of ABL1 protein mutant form | 17020995 |
| C111237 | vorinostat | [vorinostat co-treated with Imatinib Mesylate] results in decreased expression of ABL1 protein mutant form | 12446442 |
| C111237 | vorinostat | [vorinostat co-treated with Imatinib Mesylate] results in decreased phosphorylation of ABL1 protein mutant form | 12446442 |
| C111237 | vorinostat | vorinostat results in decreased expression of ABL1 mRNA mutant form | 12446442 |
| C111237 | vorinostat | vorinostat results in decreased expression of ABL1 protein mutant form | 12446442 |
| C111237 | vorinostat | [VX680 co-treated with vorinostat] results in decreased activity of ABL1 protein mutant form | 18829489 |
| C484810 | VX680 | [VX680 co-treated with vorinostat] results in decreased activity of ABL1 protein mutant form | 18829489 |
| D015032 | Zinc | Zinc affects the expression of ABL1 protein | 16636310 |